Nanjing Pharmaceutical: Baiyunshan's subsidiary Guangyao Phase II Fund intends to acquire 145 million shares of the company
I'm LongbridgeAI, I can summarize articles.
NPC has signed a strategic investment agreement with BAIYUNSHAN PH and Guangzhou Pharmaceutical Phase II Fund, under which the Guangzhou Pharmaceutical Phase II Fund intends to acquire 145 million shares of NPC, accounting for 11.04% of the total share capital. Both parties will jointly formulate market expansion plans, optimize the supply chain, enhance industrial chain cooperation, promote the transformation and upgrading of the traditional Chinese medicine industry, build a modern circulation system for Chinese medicinal materials, and promote traditional Chinese medicine culture
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments